Phase 2 N=44 Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Colorectal Cancer
Primary: 12-Week Progression Free Survival — 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=760 Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 2 N=181 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=29 Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
Phase 2 N=53 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: Objective Response — 1; 3; 2 Participants
Phase 2 N=94 A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=42 Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Recurrent Colon Carcinoma
Primary: To Examine the DLT — 200 mg
Phase 2 N=56 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 3 N=492 Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Refractory Metastatic Colorectal Cancer
Primary: Overall Survival (OS) — 10.78; 7.46 months — p=< 0.001
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=54 First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Colorectal Neoplasms
Primary: Objective Response (OR) — 0.4390 Proportion of participants — p=0.36
Phase 2 N=41 TAS-OX for Refractory Metastatic Colon Cancer
Colorectal Neoplasms
Primary: Overall Response Rate — 2.4 months
Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Phase 2 N=133 Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Carcinoma · Recurrent Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Progression Free Survival (PFS) — 4.37; 3.32 months — p=0.051
Phase 3 N=800 Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Colorectal Cancer
Primary: Overall Survival — 7.1; 5.3 months — p=<0.0001
Phase 2 N=15 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Phase 2 N=13 Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Participants With Pre-specified Treatment-related Adverse Events — 3; 5; 3 participants
Phase 2 N=131 ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal…
Phase 2 N=85 Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Phase 2 N=68 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Metastatic Colorectal Cancer · KRAS Gene Mutation
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 1; 3 Participants
Phase 3 N=1,072 A Study in Second Line Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Overall Survival (OS) — 13.3; 11.7 months — p=0.0219
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 3 N=1,226 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Colorectal Neoplasms · Neoplasm Metastasis
Primary: Overall Survival (OS) — 12.06; 13.50 months — p=0.0032
Phase 2 N=154 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Phase 3 N=768 Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Colorectal Neoplasms
Primary: Progression-Free Survival (PFS) by Central Review Assessment — 1.38; 1.51 Months — p=<0.0001